| |
References |
| (1) Nucleus and gene expression. |
|
| Binding to DNA |
|
| Binds to histone-DNA complex and induces conformational changes of chromatin. |
[20] |
| Induces topological changes of DNA. |
[21,22] |
| |
| Altered gene expression. |
|
| Induces decreased expression of neurofilament and tubulin. |
[23] |
| Induces altered expression of genes of neurofilament, APP, and neuron specific enolase. |
[24] |
| Induces decreased expression of transferrin receptor. |
[25] |
| Induces altered expression of RNA polymerase I. |
[26] |
| Induces downregulation of mitochondrial cytochrome c oxidase. |
[27] |
| Induces altered expression of calbindin-D28k. |
[28] |
| Induces decrease in the expression of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). |
[29] |
| Induces expression of pro-inflammatory genes and pro-apoptotic genes. |
[30] |
| Induces elevated expression of APP. |
[31,32] |
| Induces altered expression of oxidative stress marker genes (SOD1, glutathione reductase, etc.). |
[33] |
| Induces decreased expression of neprilysin. |
[34] |
| Induces altered expression of β-APP secretase (BACE1 and BACE2). |
[35] |
| |
| (2) Cellular functions |
|
| Energy metabolismo |
|
| Inhibits the activity of hexokinase |
[36] |
| Inhibits the activity of phosphofructokinase |
[37] |
| Inhibits the activity of glucose-6-phosphate dehydrogenase |
[38] |
| Causes mitochondrial dysfunction and depletion of ATP |
[39,40] |
| Decreases in activity and expression of TCA-cycle related enzymes (succinate dehydrogenase (SDH), alpha-ketoglutarate dehydrogenase (KGDH), isocitrate dehydrogenase-NAD+ IDH), fumarase (FUM), aconitase (ACN), and cytochrome c oxidase (Cyt C Ox)). |
[41] |
| |
| Phosphorylation and dephosphorylation |
|
| Inhibits the activity of protein phosphatase. |
[42] |
| Increases the activity of protein kinase C and cytoskeleton proteins. |
[43] |
| Accelerates phosphorylation and accumulation of neurofilament. |
[44] |
| Enhances Ca2+/Calmodulin dependent protein kinase activity. |
[45] |
| Accelerates phosphorylation of MAP 2 and neurofilament. |
[46] |
| Inhibits dephosphorylation of tau. |
[47] |
| Induces nonenzymatic phosphorylation of tau. |
[48] |
| |
| Abnormal accumulation of proteins |
|
| Causes the conformational change and the accumulation of neurofilament and MAP1A, MAP1B. |
[49] |
| Accelerates the phosphorylation of tau and its accumulation. |
[50] |
| Causes the accumulation of tau protein in neuroblastoma cells or in primary cultured neurons. |
[51,52] |
| Causes the accumulation of tau protein in experimental animals. |
[53,54] |
| Causes neurofibrillary degeneration in vivo. |
[55] |
| Causes the accumulation of AβP in cultured neurons or in neuroblastoma cells. |
[56,57] |
| Causes the accumulation of AβP in vivo. |
[58,59] |
| |
| Neurotransmitter release |
|
| Inhibits glutamate release. |
[60] |
| Impairs synaptic transmission. |
[61,62] |
| Inactivates glutamate dehydrogenase. |
[63] |
| Inhibits NMDA-type glutamate receptor. |
[64] |
| Inhibits choline acetyl transferase and tyrosine hydroxylase, glutamate decarboxylase. |
[65,66] |
| Influences acetyl-CoA and inhibits acetylcholine release. |
[67] |
| Activates monoamine oxidase. |
[68,69] |
| Inhibits dopamine beta-hydroxylase. |
[70] |
| Inhibits uptake of serotonin and noradrenalin in synaptosomes. |
[71] |
| |
| Channel inhibition |
|
| Influences the activities of Na+ channels and K+ channels. |
[72] |
| Enhances the voltage-activated Na+ channels. |
[73] |
| Inhibits the voltage-gated calcium channel. |
[62,74] |
| Inhibits the IP3-mediated Ca2+ release. |
[75] |
| |
| Others |
|
| Influences GTP binding proteins as aluminum fluoride. |
[76] |
| Inhibits GAP junction. |
[77] |
| Inhibits axonal transports. |
[78] |
| Binds to calmodulin and inhibition of calmodulin-binding enzymes. |
[79] |
| Induces inflammatory responses. |
[80] |
| |
| (3) Membrane lipids |
|
| |
| Peroxidation |
|
| Accelerates iron-induced membrane lipid peroxidation. |
[81] |
| Enhances lipid peroxidation in liposomes. |
[82] |
| Induces peroxidation of myelin lipids in vivo. |
[83] |
| Increases peroxidation products (malondialdehyde). |
[50] |
| |
| Membrane properties |
|
| Causes the change the lipid/phospholipids profiles of myelinin vivo. |
[84] |
| Induces the change in membrane physical properties (surface potential, lipid fluidity, and lipid arrangement). |
[83] |
| Induces the change of membrane fluidity. |
[85] |
| |
| (4) Higher functions |
|
| |
| Cell death |
|
| Causes the apoptotic neuronal death. |
[86,87] |
| Causes the apoptosis of astrocytes. |
[88] |
| Causes the death of motor neuron. |
[89,90] |
| |
| Behavior, learning, and memory, others |
|
| Inhibits long term potentiation (LTP). |
[91,92] |
| Causes learning disorder or memory deficit in experimental animals. |
[93–95] |
| Influences electrical activity in hippocampus and inhibits spatial learning memory deficit in aging rats. |
[96] |
| Causes memory deficit in AD model mice. |
[97,98] |
| Causes encephalopathy in dialysis patients. |
[99] |
| Causes encephalopathy in patients with renal failure. |
[100] |